HER‐2/<i>neu</i> Gene Amplification in Cervical Cancer in Chinese Women of Hong Kong and China

Wong, Yick Fu; Chung, Tony K.H.; Cheung, Tak Hong; Lam, S. K.; Tam, Oi Sin; Lu, Haizhen; Xu, Fangfang; Chang, A.M.Z.

doi:10.1111/j.1447-0756.1996.tb00961.x

Cited by 7 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in disagreement with previous HER-2/neu studies on invasive cervical carcinomas that reported a higher rate of p185 c-erbB2 overexpression or HER-2/neu gene amplification (16)(17)(18)(19)(20)(21). This finding can be explained by differences in interpretation of p185 c-erbB2 immunolabeling and by different thresholds for the definition of p185 c-erbB2 overexpression.…”

Section: Discussioncontrasting

confidence: 83%

“…Human papillomavirus (HPV) status was determined as previously described (24). Southern blot hybridization was the first-step procedure, using specific probes for HPV6, 11,16,18,31,33,35,39,42,45,52, and 58. A PCR with consensus primers in the L1 open reading frame was performed on cases negative by Southern blot hybridization.…”

Section: Methodsmentioning

confidence: 99%

“…In cervical carcinomas, amplification of the HER-2/neu gene has been found in 1.5% to 18% of the cases assessed by Southern blot, slot blot, polymerase chain reaction (PCR), or in situ hybridization (16)(17)(18)(19). The rate of overexpression of p185 c-erbB2 assessed by immunohistochemistry has ranged from 9% to 42% (17,(19)(20)(21).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix

Rosty

Couturier

Vincent‐Salomon

et al. 2004

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

The aim of this study was to investigate HER-2/neu (c-erbB2) overexpression/amplification in carcinoma of the uterine cervix using immunohistochemistry and fluorescent in situ hybridization (FISH) to assess whether anti-p185c-erbB2 therapy might have potential benefits in patients with advanced invasive cervical carcinoma. The authors used a protocol for p185c-erbB2 immunohistochemistry (clone CB11) that has been previously calibrated using FISH as the gold standard, showing a 98% accuracy rate in a large series of breast carcinomas. Immunolabeling for p185c-erbB2 was present in 24 of 82 (29%) of the tumors, but only 2 tumors (2%) with a labeling of more than 60% of the cells were considered positive for overexpression. FISH analysis did not find HER-2/neu gene amplification in these cases, although five other tumors showed weak and/or focal immunolabeling. There was no correlation between the presence of immunolabeling and age, histologic type, or clinical stage. Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients.

show abstract

Section: Discussioncontrasting

confidence: 83%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix

Rosty

Couturier

Vincent‐Salomon

et al. 2004

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

“…In endometrial adenocarcinoma the miRNA, miR-125b, inhibits the expression of HER2/neu and has been noted to be downregulated in HER2/neu-overexpressing endometrial adenocarcinoma samples [428]. Squamous cell carcinoma of the uterine cervix also expresses HER2/neu in 20-30% of the cases [10,377,415,[429][430][431][432][433][434][435][436][437] with approximately 50-75% of those cases demonstrating gene amplification [438][439][440][441][442]. Gene amplification is positively associated with the presence of HPV-6, a low -risk HPV serotype, in the cervical biopsies [443].…”

Section: Gynecologic Tumorsmentioning

confidence: 99%

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Nelson¹

2014

Clinical Investigation

View full text Add to dashboard Cite

No biological molecule in the field of oncology has been more extensively or more successfully targeted for therapeutic intent than the product of the c-erbB2 gene, HER2/neu. This is the second of a comprehensive three-part review of the foundation for and therapeutic targeting of HER2/neu. The distribution of HER2/neu overexpression and/or gene amplification by individual tumor sites and histologies will be comprehensively surveyed and described. This provides a bridge between the primarily basic science focused Part I, and the survey of clinical applications to follow in Part III. In combination, this comprehensive survey will identify opportunities and promising areas for future evaluation of HER2/neu-targeted therapies, highlighting the importance of HER2/neu as an increasingly important therapeutic target.

show abstract

“…According to previous studies, this protein is overexpressed in 12–70% of cervical cancers [7,13,14,15,16,17,18,19,20,21,22]. Overexpression of c-erbB-2 has been associated with more advanced disease stages, and a worse prognosis [13,14,15, 17,19,20,21,22]. However, these observations remain controversial and, hence, definitive conclusions cannot be drawn [7, 16, 18].…”

Section: Introductionmentioning

confidence: 99%

Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer

et al. 2009

View full text Add to dashboard Cite

Objective: The objective was to determine the impact of the coexpression of epidermal growth factor receptor (EGFR) and tumor marker c-erbB-2 on disease-free survival (DFS) and pelvic relapse-free survival (PRFS) in patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy. Methods: The expression of EGFR and c-erbB-2 was assessed by immunohistochemistry, which was centralized and blinded to outcome. Univariate and multivariate analyses were used to evaluate the impact of EGFR and c-erbB-2 on DFS and PRFS. Results: 170 patients with LACC were included and received concurrent chemoradiotherapy. 25 (15%) biopsies were considered EGFR and c-erbB-2 positive; 100 (59%) were either EGFR or c-erbB-2 positive, and 45 (26%) were EGFR and c-erbB-2 negative. The 3- and 5-year DFS was 39% each for EGFR- and c-erbB-2-positive patients, 54 and 49%, respectively, for EGFR- or c-erbB-2-positive patients, and 76 and 72%, respectively, for EGFR- and c-erbB-2-negative patients (p = 0.006). EGFR- and c-erbB-2-positive tumors were significantly associated with a decrease in PRFS (hazard ratio, HR, 3.99; 95% confidence interval, CI, 1.44–11.05, p = 0.007), and DFS (HR 2.9; 95% CI, 1.26–6.66, p = 0.01). Conclusion: Patients with LACC coexpressing EGFR and c-erbB-2, and treated with concurrent chemoradiotherapy, had a worse clinical prognosis with shorter DFS and PRFS.

show abstract

HER‐2/neu Gene Amplification in Cervical Cancer in Chinese Women of Hong Kong and China

Abstract: The results suggest that HER-2/neu amplification does exist in a subgroup of invasive cervical cancer and may play a role in cervical carcinogenesis. The role as independent prognostic factor has to be evaluated by further prospective studies.

Cited by 7 publications

References 8 publications

Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix

Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer

Contact Info

Product

Resources

About